Fesoterodine for the treatment of overactive bladder (Q37634191)

21 August 2017

1 reference

title

Fesoterodine for the treatment of overactive bladder. (English)

1 reference

21 August 2017

Maria Tzefos

1

1 reference

21 August 2017

Christian Dolder

series ordinal

2

1 reference

21 August 2017

Jacqueline L Olin

series ordinal

3

1 reference

21 August 2017

language of work or name

English

0 references

publication date

17 November 2009

1 reference

Annals of Pharmacotherapy

21 August 2017

1 reference

21 August 2017

43

1 reference

21 August 2017

12

1 reference

21 August 2017

1992-2000

1 reference

Current management of overactive bladder

21 August 2017

1 reference

The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study

21 January 2018

1 reference

A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder

21 January 2018

1 reference

Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder

21 January 2018

1 reference

A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial

21 January 2018

1 reference

Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial

21 January 2018

1 reference

Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study

21 January 2018

1 reference

Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial.

21 January 2018

1 reference

Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET).

21 January 2018

1 reference

Overactive bladder treatments in early phase clinical trials

21 January 2018

1 reference

Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa.

21 January 2018

1 reference

Antimuscarinics and the overactive detrusor--which is the main mechanism of action?

21 January 2018

1 reference

Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?

21 January 2018

1 reference

Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo

21 January 2018

1 reference

Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine

21 January 2018

1 reference

Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine

21 January 2018

1 reference

Evaluation of drug-drug interactions with fesoterodine

21 January 2018

1 reference

Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome

21 January 2018

1 reference

Fesoterodine dose response in subjects with overactive bladder syndrome

21 January 2018

1 reference

Comparison of fesoterodine and tolterodine in patients with overactive bladder

21 January 2018

1 reference

Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study

21 January 2018

1 reference

Impact of fesoterodine on quality of life: pooled data from two randomized trials

21 January 2018

1 reference

Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

21 January 2018

1 reference

Muscarinic receptor antagonists for overactive bladder treatment: does one fit all?

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1M308

1 reference

21 August 2017

1 reference